Showing results (1-10 of 456) with videos related to
Sort By:
Pageof 46
Clinical Advances in Hematology & Oncology : H&O|November 16, 2019
Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime timeDickran Kazandjian, Ola LandgrenSeminars in Oncology|January 8, 2017
A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survivalDickran Kazandjian, Ola LandgrenBlood Cancer Discovery|September 1, 2023
MRD and Plasma Cell Dynamics after CAR T-cell Therapy in MyelomaOla Landgren, Dickran KazandjianSeminars in Hematology|February 24, 2026
MRD in multiple myeloma: From an early endpoint for accelerated approval to MRD driven treatment and clinical managementOla Landgren, Rafat Abonour, Dickran KazandjianLeukemia & Lymphoma|September 5, 2022
T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscapeDickran Kazandjian, Andrew Kowalski, Ola LandgrenClinical Advances in Hematology & Oncology : H&O|February 6, 2015
Smoldering multiple myeloma: pathophysiologic insights, novel diagnostics, clinical risk models, and treatment strategiesDickran Kazandjian, Sham Mailankody, Neha Korde, et al.British Journal of Haematology|June 6, 2020
The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?Dickran Kazandjian, Clifton C Mo, Ola Landgren, et al.Current Oncology Reports|April 27, 2024
Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and OpinionsMina Meseha, James Hoffman, Dickran Kazandjian, et al.Blood Cancer Journal|May 7, 2026
MGUS prevalence among active-duty military personnelDickran Kazandjian, Christin DeStefano, Sarah Darmon, et al.Leukemia|May 20, 2021
The mutagenic impact of melphalan in multiple myelomaFrancesco Maura, Niels Weinhold, Benjamin Diamond, et al.Pageof 46